<Page>
                                                                    EXHIBIT 99.1

JOHN J. MASIZ CHAIRMAN, PRESIDENT AND CEO OF VASO
ACTIVE PHARMACEUTICALS TALKS TO THE WALL STREET TRANSCRIPT
Monday, March 8

NEW YORK--(BUSINESS WIRE)--March 8, 2004--The Wall Street Transcript has
published an in-depth interview with John J. Masiz, Chairman, President and CEO
of Vaso Active Pharmaceuticals, (NASDAQ: VAPH) in which he talks at length about
the Company.

The entire 2,500 word interview is available free online at
http://www.twst.com/ceos.htm

Vaso Active is focused on the development, commercialization, and marketing of
OTC products using the PENtoCORE(R) drug delivery system.

In describing the Company's current products Mr. Masiz states, "We have a
portfolio of 12 products that we're pulling together, everything from psoriasis,
eczema and acne. We also have a transdermal ibuprofen product that is about to
commence clinical trials. If a product is available for over-the-counter
distribution, we will have the capacity to utilize our technology with it and do
it in a much more efficient way."

Regarding the company's technology Mr. Masiz states "The great thing about our
technology is that you can be very precise with dosing. With simple studies you
can determine that. An example relative to ibuprofen: if we're in the process of
delivering 100 milligrams of ibuprofen, a little foil packet, with the gel where
the ibuprofen is preimpregnated, administers a very precise dosing."

The Wall Street Transcript does not endorse the views of any interviewees nor
does it make stock recommendations. For subscription information call
800/246-7673.

Contact:

Matt Carter
Vaso Active Pharmaceuticals
978-750-1991 Ext. 28
mcarter@vasoactive.us